Literature DB >> 30825198

Activation of PERK in ET-1- and thrombin-induced pulmonary fibroblast differentiation: Inhibitory effects of curcumin.

Yen-Chou Chen1,2,3, Bing-Chang Chen3,4, Huei-Mei Huang1,3, Shin-Hua Lin1,3, Chien-Huang Lin1,3.   

Abstract

In the present study, we investigated the role of PKR-like endoplasmic reticular kinase (PERK), an endoplasmic reticulum (ER) stress kinase, in endothelin 1 (ET-1)- and thrombin-induced pulmonary fibrosis (PF), and the preventive effects of curcumin (CUR). Using the human embryonic WI-38 lung fibroblast cell line, ET-1 and thrombin induced the expression of ER stress-related proteins (CCAAT-enhancer-binding protein homologous protein, PERK, and binding immunoglobulin protein), a profibrogenic factor (cellular communication network factor 2 [CCN2]), and differentiation markers including α-smooth muscle actin (α-SMA), collagen I (Col I), and Col IV. Knockdown of PERK expression via small interfering RNA (siRNA) significantly reduced the increases in CCN2, α-SMA, Col I, and Col IV proteins in WI-38 cells according to western blot analysis and immunohistochemistry (IHC). Activation of c-Jun N-terminal kinase (JNK) was observed in ET-1- and thrombin-treated WI-38 cells, and the addition of a JNK inhibitor (SP) suppressed the induction of the indicated proteins by ET-1 and thrombin. Thapsigargin (TG), an ER stress inducer, elevated expressions of PERK and ER stress-related proteins with increased differentiation of WI-38 cells. Knockdown of PERK by siRNA or the PERK inhibitor glycogen synthesis kinase reduced expressions of the differentiation markers, α-SMA and Col IV, in WI-38 cells. CUR concentration-dependently inhibited ET-1- or thrombin-induced CCN2, α-SMA, and vimentin proteins with decreased levels of phosphorylated mitogen-activated protein kinase and PERK in WI-38 cells. An in vivo bleomycin-induced PF study showed that an intraperitoneal injection of CUR (30 mg/kg) reduced expressions of α-SMA, CCN2, Col IV, and vimentin in lung tissues via IHC staining using specific antibodies. This study is the first to demonstrate that PERK activation contributes to pulmonary fibroblast differentiation elicited by ET-1 or thrombin, and the inhibitory activity of CUR against PF is demonstrated herein.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  ERK; curcumin; endothelin 1; lung fibrosis; thrombin

Year:  2019        PMID: 30825198     DOI: 10.1002/jcp.28256

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

1.  AQP1 suppression by ATF4 triggers trabecular meshwork tissue remodelling in ET-1-induced POAG.

Authors:  Yingying Zhao; Huazhang Zhu; Yangfan Yang; Yiming Ye; Youli Yao; Xiaoyan Huang; Yixiang Zhang; Xingsheng Shu; Xianxiong Chen; Yatao Yang; Junxian Ma; Le Cheng; Xiaomei Wang; Ying Ying
Journal:  J Cell Mol Med       Date:  2020-02-13       Impact factor: 5.310

Review 2.  Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis.

Authors:  Cristina Estornut; Javier Milara; María Amparo Bayarri; Nada Belhadj; Julio Cortijo
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

Review 3.  The Role of Endoplasmic Reticulum Stress in Differentiation of Cells of Mesenchymal Origin.

Authors:  Ekaterina Turishcheva; Mariya Vildanova; Galina Onishchenko; Elena Smirnova
Journal:  Biochemistry (Mosc)       Date:  2022-09       Impact factor: 2.824

4.  Mechanism of Yifei Decoction Combined with MitoQ on Inhibition of TGFβ1/NOX4 and PDGF/ROCK Signal Pathway in Idiopathic Pulmonary Fibrosis.

Authors:  Lijuan Chen; Chengzhong Lan; Hong Xiao; Xiaoli Zhang; Xiangrong Qi; Li Ouyang; Yanbin Yang; Fengying Wang; Qihua Jin; Yi Sun
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-28       Impact factor: 2.629

5.  Endothelin 1-induced retinal ganglion cell death is largely mediated by JUN activation.

Authors:  Olivia J Marola; Stephanie B Syc-Mazurek; Gareth R Howell; Richard T Libby
Journal:  Cell Death Dis       Date:  2020-09-26       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.